STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
STAT News · LC · trust 58/100
The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
Read the original at STAT News →
Open in TruthVane →